Lakefront Biotherapeutics (LKFT) Gross Profit (2016 - 2026)

Lakefront Biotherapeutics (LKFT) has 11 years of Gross Profit data on file, last reported at $2.0 million in Q1 2026.

• Gross Profit for Q1 2026 came in at $2.0 million, down 96.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 403.05% YoY), and the FY2025 annual result was $1.3 billion, up 389.73% from the prior year.
• Gross Profit eased to $2.0 million in Q1 2026 per LKFT's latest filing, from $1.0 billion in the prior quarter.
• Over five years, Gross Profit peaked at $1.0 billion in Q4 2025 and troughed at -$176.6 million in Q4 2022.
• A 5-year average of $147.1 million and a median of $64.7 million in 2025 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2024 and 2025: Gross Profit slumped 145.68% in 2024, then jumped 2639.63% in 2025.
• A 5-year view of Gross Profit shows it stood at -$176.6 million in 2022, then surged by 420.43% to $565.7 million in 2023, then tumbled by 93.24% to $38.3 million in 2024, then jumped by 2639.63% to $1.0 billion in 2025, then slumped by 99.81% to $2.0 million in 2026.
• Business Quant data shows LKFT's Gross Profit at $2.0 million in Q1 2026, $1.0 billion in Q4 2025, and $49.6 million in Q3 2025.